TY - JOUR
T1 - Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
AU - Dispenzieri, Angela
AU - Krishnan, Amrita
AU - Arendt, Bonnie
AU - Blackwell, Beth
AU - Wallace, Paul K.
AU - Dasari, Surendra
AU - Vogl, Dan T.
AU - Efebera, Yvonne
AU - Fei, Mingwei
AU - Geller, Nancy
AU - Giralt, Sergio
AU - Hahn, Theresa
AU - Howard, Alan
AU - Kohlhagen, Mindy
AU - Landau, Heather
AU - Hari, Parameswaran
AU - Pasquini, Marcelo C.
AU - Qazilbash, Muzaffar H.
AU - McCarthy, Philip
AU - Shah, Nina
AU - Vesole, David H.
AU - Stadtmauer, Edward
AU - Murray, David
N1 - Funding Information:
This manuscript was prepared using BMT CTN 0702 and BMT CTN 07LT Research Materials obtained from the NHLBI and data from the BMT CTN 0702 Ancillary Study PRIMeR—Prognostic Immunophenotype for Myeloma Response, National Heart, Lung, and Blood Institute (NHLBI) grant # R01HL107213. The Blood and Marrow Transplant Clinical Trials Network funded by grant #U10HL069294 from the NHLBI and the National Cancer Institute. The BMT CTN 0702 and 07LT were also supported by Celgene Corporation (now Bristol Myers Squibb) and Millennium Pharmaceuticals, Inc., and funding by the The Alliance for Clinical Trials in Oncology, the ECOG-ACRIN Cancer Research Group, and SWOG. The CIBMTR registry is supported primarily by U24CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and by contract HHSH234200637015C to the Center for International Blood and Marrow Transplant Research from HRSA/DHHS. This ancillary study was also supported by Grant Number P30 CA015083 and CA186781 from the National Cancer Institute and by the Predolin Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above-mentioned parties.
Funding Information:
This manuscript was prepared using BMT CTN 0702 and BMT CTN 07LT Research Materials obtained from the NHLBI and data from the BMT CTN 0702 Ancillary Study PRIMeR?Prognostic Immunophenotype for Myeloma Response, National Heart, Lung, and Blood Institute (NHLBI) grant # R01HL107213. The Blood and Marrow Transplant Clinical Trials Network funded by grant #U10HL069294 from the NHLBI and the National Cancer Institute. The BMT CTN 0702 and 07LT were also supported by Celgene Corporation (now Bristol Myers Squibb) and Millennium Pharmaceuticals, Inc., and funding by the The Alliance for Clinical Trials in Oncology, the ECOG-ACRIN Cancer Research Group, and SWOG. The CIBMTR registry is supported primarily by U24CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and by contract HHSH234200637015C to the Center for International Blood and Marrow Transplant Research from HRSA/DHHS. This ancillary study was also supported by Grant Number P30 CA015083 and CA186781 from the National Cancer Institute and by the Predolin Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above-mentioned parties.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/2
Y1 - 2022/2
N2 - Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.
AB - Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.
UR - http://www.scopus.com/inward/record.url?scp=85124447448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124447448&partnerID=8YFLogxK
U2 - 10.1038/s41408-022-00624-6
DO - 10.1038/s41408-022-00624-6
M3 - Article
C2 - 35145071
AN - SCOPUS:85124447448
SN - 2044-5385
VL - 12
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 2
M1 - 27
ER -